Literature DB >> 25401088

A single case of rosai-dorfman disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribine.

Koji Sasaki1, Naveen Pemmaraju1, Jason R Westin2, Wei-Lien Wang3, Joseph D Khoury4, Donald A Podoloff5, Bryan Moon6, Naval Daver1, Gautam Borthakur1.   

Abstract

Rosai-Dorfman disease (RDD) is a proliferative histiocytic disorder of unknown etiology, which is characterized by sinus histiocytosis with massive lymphadenopathy (1). In most cases, RDD has a benign course and treatment is not necessary. However, severe cases of RDD require treatment, and the treatment strategy is determined on the basis of the severity of the disease or the extranodal involvement of vital organs. We report a single case of RDD with atypical presentation of persistent constitutional symptoms, progressing pathologic fractures, and end-organ dysfunction, including acute kidney failure and liver cirrhosis with esophageal varices.

Entities:  

Keywords:  CD163; Rosai–Dorfman disease; S-100; cladribine; histiocytes

Year:  2014        PMID: 25401088      PMCID: PMC4212618          DOI: 10.3389/fonc.2014.00297

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


A 55-year-old African American woman presented with a 10-month history of night sweats, fever, weight loss, and hepatosplenomegaly. The patient had experienced an episode of transient renal failure requiring 2 weeks of dialysis 3 months before presentation. Her initial physical exam was significant for no palpable lymphadenopathy. Positron emission tomography/computed tomography at presentation showed 18F fluorodeoxyglucose-avid right cardiophrenic, periportal, left gastric, and peripancreatic lymphadenopathy with a maximum node diameter of 3.5 cm and a maximum standard uptake value of 5.0; hepatosplenomegaly with craniocaudal dimensions of 22 and 14 cm for the liver and spleen, respectively; and non-displaced rib fractures at right sixth and seventh ribs. Excisional biopsy of a right axillary lymph node revealed reactive lymph node changes characterized primarily by mantle zone and marginal zone hyperplasia with few small residual germinal centers. Multiple small non-necrotizing granulomas were identified. Sinuses were reactive and contained unremarkable sinus histiocytes without discernible emperipolesis. Immunohistochemistry showed B-cell predominance with minimal paracortical expansion. Bone marrow biopsy demonstrated that 40–50% of cellularity with trilineage hematopoiesis. There was no morphologic evidence of infiltration by leukemia, lymphoma, or other malignancy. Liver biopsy showed established cirrhosis, perisinusoidal fibrosis with prominent proliferation of bile ductal cells, and mild inflammation (predominantly small lymphocytes with a few plasma cells). Esophagogastroduodenoscopy revealed esophageal varices and small varices in the gastric fundus. Eight months after presentation, the patient developed pathologic fracture of the left ischium. Positron emission tomography/computed tomography showed a lytic lesion involving the left inferior pubic ramus with a soft tissue component measuring 2.5 cm × 1.8 cm and an associated non-displaced cortical fracture of the left inferior pubic ramus at the site of the lytic lesion (Figure 1).
Figure 1

Positron emission tomography/computed tomography of the pelvis showed a hypermetabolic lytic lesion with a pathologic fracture involving the left inferior pubic ramus with maximum SUV 15.1 associated with a soft tissue mass 2.5 cm. × 1.8 cm.

Positron emission tomography/computed tomography of the pelvis showed a hypermetabolic lytic lesion with a pathologic fracture involving the left inferior pubic ramus with maximum SUV 15.1 associated with a soft tissue mass 2.5 cm. × 1.8 cm. Surgical biopsy of the left ischium revealed a mixed inflammatory infiltrate composed of large histiocytes, lymphocytes, and plasma cells. The histiocytes demonstrated emperipolesis and were reactive for both CD163 and S-100 proteins; consistent with Rosai–Dorfman disease (RDD) (Figure 2).
Figure 2

Left ischium biopsy. (A) Collections of histiocytes admixed with lymphocytes are seen involving bone (H&E, 100×). (B) High power reveals the histiocytes demonstrate emperipolesis, engulfing lymphocytes (H&E, 400×). Immunohistochemical studies reveal that the histiocytes co-express (C) CD163 and (D) S-100 protein.

Left ischium biopsy. (A) Collections of histiocytes admixed with lymphocytes are seen involving bone (H&E, 100×). (B) High power reveals the histiocytes demonstrate emperipolesis, engulfing lymphocytes (H&E, 400×). Immunohistochemical studies reveal that the histiocytes co-express (C) CD163 and (D) S-100 protein. The patient was given single-agent cladribine, 5 mg/m2, for days 1 through 5 in 28-day cycles. After five cycles of single-agent cladribine, magnetic resonance imaging confirmed complete resolution of the soft tissue mass in the pubic ramus and a well-healed pathologic fracture. Repeat positron emission tomography/computed tomography showed residual multicompartmental adenopathy and demonstrated no visible 18F fluorodeoxyglucose uptake. In our patient, the surgical biopsy of the left ischium demonstrated histiocyte emperipolesis and CD163 and S-100 protein expression. The presence of emperipolesis by histiocytes, which are positive for S-100 and CD163, is diagnostic of RDD (2–4). Our patient’s clinical presentation was atypical because of liver cirrhosis, kidney involvement, and confirmed pathologic fractures. The most frequent clinical presentation of RDD is massive bilateral, painless cervical lymphadenopathy with constitutional symptoms including fever, night sweats, and weight loss (5). Skeletal lesions of RDD are typically osteolytic and can be confused radiographically with Langerhans cell histiocytosis (5). Extranodal involvement is commonly observed in the upper respiratory tract, skin, and soft tissue and less commonly observed in cases with thyroid, kidney, and skeletal involvement including spine (5–9). 18F fludeoxyglucose positron emission tomography can detect the metabolically highly active lesions of RDD (10). RDD often takes a self-limited benign course with frequent incidence of spontaneous resolution; nevertheless, approximately 10% of patients die of RDD due to the extranodal involvement in multiple sites and the progressive proliferation or relapse of systemic lymphadenopathy over several years (11). In our patient, the persistent constitutional symptoms, progressive pathologic fractures, and end-organ dysfunction – including a previous episode of kidney failure requiring dialysis and liver cirrhosis with esophageal varices – justified further intervention. Results with chemotherapeutic agents have not been encouraging, although case reports or case series have demonstrated clinical benefits or responses in patients with RDD treated with cladribine (12–15). In our patient, treatment with five cycles of cladribine resulted in radiographic improvement and stable lymphadenopathy without 18F fluorodeoxyglucose uptake. In conclusion, the use of chemotherapy should be restricted to patients whose disease is life-threatening, does not respond to conservative treatments, or relapses multiple times after other treatments since RDD is self-limited in most patients. We report a single case of RDD in which treatment with single-agent cladribine resulted in symptom improvement.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
  15 in total

1.  Extranodal Rosai-Dorfman disease: a solitary lesion with soft tissue reaction.

Authors:  Mototaka Miyake; Ukihide Tateishi; Tetsuo Maeda; Yasuaki Arai; Kazuro Sugimura; Tadashi Hasegawa
Journal:  Radiat Med       Date:  2005-09

2.  Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease) treated with 2-chlorodeoxyadenosine.

Authors:  M Tasso; C Esquembre; E Blanco; C Moscardó; M Niveiro; A Payá
Journal:  Pediatr Blood Cancer       Date:  2006-10-15       Impact factor: 3.167

3.  Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction.

Authors:  F Bernard; C Thomas; Y Bertrand; M Munzer; J Landman Parker; M Ouache; V Minard Colin; Y Perel; P Chastagner; C Vermylen; J Donadieu
Journal:  Eur J Cancer       Date:  2005-04-07       Impact factor: 9.162

Review 4.  Immunophenotypic characterization of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease).

Authors:  R N Eisen; P J Buckley; J Rosai
Journal:  Semin Diagn Pathol       Date:  1990-02       Impact factor: 3.464

5.  Primary Rosai-Dorfman disease of bone: a clinicopathologic study of 15 cases.

Authors:  Elizabeth G Demicco; Andrew E Rosenberg; Johannes Björnsson; Leon D Rybak; K Krishnan Unni; G Petur Nielsen
Journal:  Am J Surg Pathol       Date:  2010-09       Impact factor: 6.394

6.  Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity.

Authors:  J Rosai; R F Dorfman
Journal:  Arch Pathol       Date:  1969-01

7.  Rosai-Dorfman disease of the parotid gland: cytologic and histopathologic findings with immunohistochemical correlation.

Authors:  R Juskevicius; J L Finley
Journal:  Arch Pathol Lab Med       Date:  2001-10       Impact factor: 5.534

8.  PET imaging of Rosai-Dorfman disease: correlation with histopathology and ex-vivo beta-imaging.

Authors:  Christian Menzel; Nadja Hamscho; Natascha Döbert; Frank Grünwald; Adorján F Kovács; Manfred Wolter; Maurizio Podda
Journal:  Arch Dermatol Res       Date:  2003-10-18       Impact factor: 3.017

9.  Extranodal Rosai-Dorfman disease of the kidney.

Authors:  Alireza Abdollahi; Farid A Ardalan; Mohsen Ayati
Journal:  Ann Saudi Med       Date:  2009 Jan-Feb       Impact factor: 1.526

10.  Extranodal multifocal Rosai-Dorfman disease: response to 2-chlorodeoxyadenosine treatment.

Authors:  Ceyla Konca; Zübeyde N Özkurt; Müge Deger; Zeynep Akı; Münci Yağcı
Journal:  Int J Hematol       Date:  2008-11-20       Impact factor: 2.490

View more
  4 in total

Review 1.  Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease.

Authors:  Oussama Abla; Eric Jacobsen; Jennifer Picarsic; Zdenka Krenova; Ronald Jaffe; Jean-Francois Emile; Benjamin H Durham; Jorge Braier; Frédéric Charlotte; Jean Donadieu; Fleur Cohen-Aubart; Carlos Rodriguez-Galindo; Carl Allen; James A Whitlock; Sheila Weitzman; Kenneth L McClain; Julien Haroche; Eli L Diamond
Journal:  Blood       Date:  2018-05-02       Impact factor: 22.113

2.  Acute Tubulointerstitial Nephritis in Rosai-Dorfman Disease Mimicking IgG4-related Disease.

Authors:  Satoshi Kurahashi; Naohiro Toda; Masaaki Fujita; Katsuya Tanigaki; Jun Takeoka; Hisako Hirashima; Eri Muso; Katsuhiro Io; Takaki Sakurai; Toshiyuki Komiya
Journal:  Intern Med       Date:  2021-09-18       Impact factor: 1.282

3.  Osseous Rosai-Dorfman disease of tibia in children: A case report.

Authors:  Djandan Tadum Arthur Vithran; Jian-Zhou Wang; Feng Xiang; Jie Wen; Sheng Xiao; Wen-Zhong Tang; Qian Chen
Journal:  World J Clin Cases       Date:  2021-02-26       Impact factor: 1.337

4.  Rosai-Dorfman disease mimicking images of meningiomas: Two case reports and literature review.

Authors:  Rafael Trindade Tatit; Paulo Eduardo Albuquerque Zito Raffa; Giovana Cassia de Almeida Motta; André Alexandre Bocchi; Júlia Loripe Guimaraes; Paulo Roberto Franceschini; Paulo Henrique Pires de Aguiar
Journal:  Surg Neurol Int       Date:  2021-06-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.